Generic Name and Formulations:
Cefotaxime sodium 500mg, 1g, 2g, 10g; IM or IV inj; sodium content 2.2mEq/g.
Indications for CLAFORAN:
Susceptible bacteremia, septicemia, lower respiratory and genitourinary tracts, skin and skin structure, bone and joint, gynecologic, CNS (eg, meningitis), intraabdominal infections. Surgical prophylaxis.
Uncomplicated infections: 1g every 12 hours. Moderate-to-severe infections: 1–2g every 8 hours. Infections commonly needing a higher dosage (eg, septicemia): 2g IV every 6–8 hours. Life-threatening infections: 2g IV every 4 hours. Gonococcal urethritis or cervicitis: 0.5g IM once. Rectal gonorrhea: 0.5g (women) or 1g (men) IM once. All: max 12g/day. Post-op prophylaxis: give 1g as single dose 30–90mins before surgery. Cesarean section: 1st dose: 1g IV as soon as umbilical cord clamped; 2nd and 3rd dose: 1g at 6 and 12 hours after 1st dose. CrCl <20mL/min/1.73m2: consider reducing dose by one-half.
Neonates up to 1 week of age: 50mg/kg IV every 12 hours. 1–4 weeks of age: 50mg/kg IV every 8 hours. Over 1 month of age (<50kg): 50–180mg/kg in 4–6 equally divided doses. ≥50kg: as adult; max 12g/day.
Penicillin or other allergy. Monitor blood counts in treatments >10 days. Renal impairment, reduce dose. GI disease (esp. colitis). Avoid extravasation. Pregnancy (Cat.B). Nursing mothers.
Increased nephrotoxicity with concomitant aminoglycosides, NSAIDs, furosemide. Potentiated by probenecid; avoid cefotaxime doses >6g/day. May cause false (+) Fehling's or Benedict's soln, Clinitest, or Coomb's test.
Inj site reactions, colitis, diarrhea, nausea, vomiting, hypersensitivity (discontinue if occurs); blood dyscrasias, elevated liver enzymes (rare).
Vials (500mg)—10; (1g, 2g)—10, 25, 50; Infusion bottles (1g, 2g)—10; Bottles (10g)—1; Premixed inj soln—12
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|